AUTHORS
Qin Tang, PhD, Samuel Koo, MS2, Madhuri Paul, PhD3, Pathum Kanagasunderam, MS4, Roya Hariri, BS5, Michail Schizas, MS6, John M. Furgason, PhD7, Frank Scarpa, MS8, Sugganth D. Pillei, MD9, Ryan Bender, PhD10, Nathan Montgomery, MD, PhD11, Ying Wang, MD, PhD12
AFFILIATIONS
1 NeoGenomics Laboratories, Inc., Aliso Viejo, California, United States
2 NeoGenomics Laboratories, Inc., Aliso Viejo, California, United States
3 NeoGenomics Laboratories, Inc., Aliso Viejo, California, United States
4 NeoGenomics Laboratories, Inc., Aliso Viejo, California, United States
5 NeoGenomics Laboratories, Inc., Aliso Viejo, California, United States
6 NeoGenomics Laboratories, Inc., Aliso Viejo, California, United States
7 NeoGenomics Laboratories, Inc., Aliso Viejo, California, United States
8 NeoGenomics Laboratories, Inc., Aliso Viejo, California, United States
9 NeoGenomics Laboratories, Inc., Aliso Viejo, California, United States
10 NeoGenomics Laboratories, Inc., Aliso Viejo, California, United States
11 NeoGenomics Laboratories, Inc., Aliso Viejo, California, United States
12 NeoGenomics Laboratories, Inc., Aliso Viejo, California, United States
ABSTRACT
Background:
Acute myeloid leukemia (AML) is a genetically heterogeneous malignancy in which NPM1 is among the most frequently mutated genes. Pathogenic NPM1 alterations are overwhelmingly exon 12 frameshift variants, including Types A/B/D and other deletion-insertion events that converge on producing a C-terminal truncated protein (e.g., p.W288Cfs*12). Recently, rare but recurrent NPM1 exon 5 in-frame insertions have been reported, suggesting that pathogenic NPM1 alterations may extend beyond the canonical exon 12 hotspot. However, the clinicopathologic and molecular features of these variants remain poorly defined due to limited number of reported cases. This knowledge gap contributes to under-recognition of exon 5 insertion variants in current diagnostic practice, as assays designed to detect only canonical exon 12 mutations would fail to identify these uncommon variants, potentially affecting diagnosis and measurable residual disease (MRD) assessment. Here, we performed a comprehensive genomic and clinical characterization of the largest cohort to date of AML cases harboring NPM1 exon 5 in-frame insertions.
Methods/Results:
We reviewed 4,707 cases with NPM1 variants identified by Neo Comprehensive® Heme Cancers/Myeloid Disorders and NeoTYPE® Heme, Myeloid, AML, and MDS/CMML panels between January 1, 2019, and July 9, 2026. This cohort included pathogenic/likely pathogenic variants and selected variants of uncertain significance (VUS). Most cases (4,663/4,707, 99.1%) harbored frameshift mutations, including 4,622 (98.2%) with the canonical exon 12 frameshift variants, and 41 (0.9%) with alternative frameshift variants.
Notably, 39 patients (0.8%) harbored rare but recurrent NPM1 exon 5 in-frame insertions. These exon 5 variants clustered within codons 131-139 and were mutually exclusive with exon 12 canonical frameshift mutations. Exon 5 in-frame insertions were located within the central acidic domain of NPM1 and frequently contained leucine-rich insertions. Many represented short duplications or sequence variants of the native EDVKLL sequence, resulting in convergence on related KLL-, KLLS-, or VKLL-containing motifs despite underlying sequence heterogeneity. In contrast to exon 12 canonical frameshift mutations which disrupt the C-terminal nucleolar localization signal (NoLS) and promote cytoplasmic localization, exon 5 in-frame insertions introduce a nuclear export signal (NES) while preserving the C-terminal NoLS, and are predicted to produce mixed nucleolar-cytoplasmic localization.
NPM1 exon 5 in-frame insertions were observed predominantly in patients with AML. The median age of patients with an exon 5 mutation was 69 years, with a balanced sex distribution (51.3% males and 48.7% females). Among 34 patients with available diagnostic information, 30 (88.2%) had AML. Of 24 patients with available cytogenetic data, 17 (70.8%) exhibited a normal karyotype, a frequency slightly lower than AML with canonical NPM1 mutations (2,153/2,600, 82.8%). Among 13 patients with immunophenotypic data, 11 (84.6%) had CD34-negative blasts, a finding frequently observed in NPM1-mutated AML. The co-mutation profile largely mirrored that of canonical exon 12 frameshift-mutated AML, with frequent alterations in DNMT3A (35.9%), FLT3 (30.8%), IDH1/2 (43.6%), and KRAS/NRAS (23.1%). Notably, TP53 loss-of-function mutations were significantly enriched in exon 5 insertion cases compared with canonical exon 12 frameshift cases (12.8% vs. 1.5%; adjusted Fisher's exact p = 0.0325), suggesting potential biological distinctions between these NPM1 variant subtypes.
Conclusions:
We report the largest cohort to date of recurrent NPM1 exon 5 in-frame insertions. These variants cluster at codons 131-139, share conserved leucine-rich motifs, and occur predominantly in AML, with clinicopathologic features that largely resemble canonical NPM1-mutated AML with exon 12 frameshift variants. Compared with canonical cases, exon 5 insertion had enrichment of TP53 co-mutations and a modestly higher frequency of cytogenetic abnormalities. Collectively, these findings support a leukemogenic role for NPM1 exon 5 insertions mediated through mechanisms that overlap with, yet are distinct from, those of canonical exon 12 mutations. Recognition of these variants expands the spectrum of pathogenic NPM1 alterations and has important implications for AML diagnosis, risk stratification, therapy selection, and MRD monitoring.
DISCLOSURES
Qin Tang, PhD: NeoGenomics Laboratories, Inc. - Current Employment